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The virally encoded chemokine receptors US28 from human cytomegalovirus and ORF74 from human herpesvirus 8 are both
constitutively active. We show that both receptors constitutively activate the transcription factors nuclear factor of activated T cells (NFAT)
and cAMP response element binding protein (CREB) and that both pathways are modulated by their respective endogenous receptor ligands.
By addition of specific pathway modulators against the G protein subunit Gai, phospholipase C, protein kinase C, calcineurin, p38 MAP
kinase, and MEK1, we find that the constitutive and ligand-dependent inductions are mediated by multiple yet similar pathways in both
receptors. The NFAT and CREB transcription factors and their upstream activators are known inducers of host and virally encoded genes. We
propose that the activity of these virally encoded chemokine receptors coordinates host and potentially viral gene expression similarly. As
ORF74 is a known inducer of neoplasia, these findings may have important implications for cytomegalovirus-associated pathogenicity.
D 2004 Elsevier Inc. All rights reserved.Keywords: Virally encoded chemokine receptor; Constitutive activity; Transcription activation; Cytomegalovirus; HCMV; Human herpesvirus 8; HHV8Introduction
The presence of chemokines and chemokine receptors
within herpes- and poxvirus genomes has been known for
little more than a decade. These genes have presumably
been acquired through ancient acts of molecular piracy of
host-encoded chemokine ligands and receptors. Through
multiple mutations and selection pressure, the viruses have
optimized these genes to serve purposes in viral dissemina-
tion, immune evasion, and replication (Murphy, 2001).
ORF74 encoded by the human herpesvirus 8 (HHV8, also
known as Kaposi’s Sarcoma-associated herpesvirus, KSHV)
has analogs in a wide range of g2 herpesviruses (Karlin
et al., 1994) and has presumably evolved through modifi-
cation of the mammalian chemokine receptor CXCR2 with0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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Schwartz, 2000). ORF74 has been shown to signal consti-
tutively through Gaq and Gai (Bais et al., 1998; Couty
et al., 2001; Rosenkilde et al., 1999) and to activate para-
crine growth factors implicated in Kaposi’s sarcoma (Bais et
al., 1998), an endothelial-derived neoplasm of the skin. In
addition, expression of ORF74 in transgenic mice results in
an angioproliferative phenotype with resemblance to human
Kaposi’s sarcoma, thus identifying the receptor as an
important molecular trigger of Kaposi’s sarcoma pathogen-
esis (Montaner et al., 2003; Yang et al., 2000). The
constitutive activity of ORF74 can be modulated positively
by neutrophil chemoattractants such as CXCL11, -2 and, -3/
GROa, -h, and -g and negatively by the lymphocyte
chemoattractants CXCL10/IP10 and CXCL4/SDF-1 (Arva-1 The chemokine nomenclature is given according to ‘‘International
union of pharmacology. XXII Nomenclature for chemokine receptors’’
(Murphy et al., 2000) proceeded by the ‘‘old’’ previously used chemokine
name.
K.A. McLean et al. / Virology 325 (2004) 241–251242nitakis et al., 1997; Bais et al., 1998; Geras-Raaka et al.,
1998a; Rosenkilde et al., 1999).
Human cytomegalovirus (CMV) encodes four 7TM
receptors US28, US27, UL33, and UL78 of which at least
the first three shares homology to mammalian CC-chemo-
kine receptors (Bankier et al., 1991; Neote et al., 1993).
The most extensively studied of these is the constitutively
active receptor encoded by open reading frame US28. This
receptor is not present in rodent CMV, yet simian CMV
encodes no less than five variants of this receptor, strongly
suggesting important roles for US28 and its analogs in the
survival of primate CMV (Martin, 2000; Sahagun-Ruiz
et al., 2004). It was recently published that the human
CMV encoded US28, the M33 from murine CMV and the
R33 from rat CMV, but not the UL33 from human CMV,
share similar levels of constitutive activity, suggesting that
at least the US28 signaling function is conserved in rodent
CMV (Waldhoer et al., 2002). Furthermore, it has recently
been shown that US28 expression in HCMV-infected cells
is responsible for the high constitutive and pertussis toxin
(Ptx) insensitive activity observed in these cells because
the deletion mutant of HCMV lacking US28 had impaired
constitutive activation (Minisini et al., 2003). Human
CMV is a known pathogen in AIDS-associated diseases
and some reports suggest links of atherosclerosis and
restenosis to active CMV infection (Reinhardt et al.,
2002; Streblow et al., 1999). The virus has tropism for
epithelial cells, smooth muscle cells, B cells, and macro-
phages and is known to establish latent infections in the
arterial epithelium and musculature. In this context, US28
may have particular importance as it has been shown to
mediate the migration of vascular arterial smooth muscle
cells—the accumulation of which is an essential compo-
nent of atherosclerosis (Reinhardt et al., 2002; Streblow
et al., 1999). Like ORF74, US28 binds a broad spectrum
of chemokines, yet from the CC- and CX3C-family.
Agonism by CC-chemokines for US28 has been shown
in certain cellular systems (Haskell et al., 2000; Kuhn
et al., 1995), yet in other contexts this agonism has been
difficult to confirm (Casarosa et al., 2001; Waldhoer et al.,
2002). Recently, it was shown that the agonism is highly
dependent of surface expression (Waldhoer et al., 2003),
and given the low percentage of US28 being actually
expressed on the cell surface (Fraile-Ramos et al., 2001),
this explains the functional silence in respect of agonism.
The epithelial expressed CX3CL1/fractalkine functions as
a partial inverse agonist (Casarosa et al., 2001). The CC
and CX3CL-chemokines are all expressed in various stages
of atherosclerosis and during vascular inflammation thus
raising the possibility of modulation of US28 during
inflammation of the arterial vessels (Greaves et al., 2001;
Seino et al., 1995).
Multiple signaling pathways have been described for
both ORF74 and US28 from the use of G proteins and
activation of various kinases to the regulation of transcrip-
tion factors such as nuclear factor nB (NFnB) and acti-vating protein 1 (AP1) (Arvanitakis et al., 1997; Casarosa
et al., 2001; Couty et al., 2001; Rosenkilde et al., 1999,
2001; Schwarz and Murphy, 2001). The constitutive phos-
pholipase C (PLC) activation by both receptors is well
described (Arvanitakis et al., 1997; Casarosa et al., 2001;
Minisini et al., 2003; Rosenkilde et al., 1999), whereas less
is known about the relative contribution of the various
signaling cascades on the transcription activation. Here we
have focused on the signaling integrators NFAT and CREB
and characterized these in parallel for US28 and ORF74.
NFAT refers to a family of transcription activators that
participate in the development of important vertebrate-
specific functions like immune and vascular system regu-
lators (Graef et al., 2001b), most commonly associated
with the activation of Gaq. NFAT proteins elicit their
action most efficiently in association with AP-1 (fos/jun
heterodimer) and the NFAT pathway is primarily consid-
ered as an integrator of gene transcription (Macian et al.,
2001). Two members, NFATc3 and NFATc4, have been
shown to play a crucial role in vascular development and
are linked to transcription of VEGF and its tyrosine-kinase
receptors VEGF-R2/flk-1 and VEGF-R1/flt-1 (Graef et al.,
2001a). NFAT is regulated selectively by the Ca2+-depen-
dent phosphokinase calcineurin that mediates the activation
and translocation of the cytoplasmic distributed NFAT to
the nucleus by dephosphorylating NFAT. The nuclear
NFAT is rapidly rephosphorylated by glycogen synthase
kinase-3 and exported to the cytoplasm—thus NFAT-me-
diated transcription requires a sustained low calcium influx
to the cytoplasm (Rao et al., 1997). CREB is a transcrip-
tion activator linked to a broad range of cellular processes,
including proliferation, differentiation, and adaptive
responses, most commonly associated with the cAMP
activation by Gas.
In the following, we demonstrate constitutive activation
of the transcription factors NFAT and CREB by both US28
and ORF74. Using reporter assays, we show that this
induction is mediated by multiple and similar pathways.
Our results suggests that the viruses have used these
receptors to serve similar purposes in transcription activa-
tion and cellular programming and accordingly that differ-
ences in the biological properties of these receptors must be
reflected in their ligand-binding pattern.Results
ORF74 and US28 constitutively activate NFAT activity
A dose-dependent increase in basal NFAT activation was
observed for both receptors in transiently transfected HEK-
293 cells. An 80-fold increase in basal activity above the
level for the empty vector pTEJ8 was observed for ORF74
(Fig. 1A), while US28 showed an activation at about
25-fold corresponding to approximately one-third of the
equivalent ORF74 activity level (Fig. 1B). The experiments
Fig. 1. ORF74 and US28 constitutively activate NFAT cis-reporting system
in a dose-dependent manner. HEK-293 cells were transiently transfected
with NFAT reporter plasmid (pNFAT-Luc) as described in Materials and
methods together with increasing amounts of receptor cDNA. (A) ORF74
(o), CXCR2 (4), and empty vector pTEJ8 (n). (B) US28 (5) and pTEJ8
(n). (N = 4–5 for all experiments).
Fig. 2. Chemokine modification of ORF74- and US28-mediated NFAT
activation. HEK-293 cells were transiently transfected with ORF74 and
NFAT reporter (pNFAT-Luc) and were treated with increasing concen-
trations of the chemokines CXCL1/GROa (5), CXCL8/IL8 (E),
CXCL10/IP10 (n) (A). In B, US28 under influence of 107 M of different
chemokines, CCL5/RANTES (black bar), CCL1/MCP1 (lined bar), and
CX3CL1/fractalkine (light gray bar) is shown together with the effect of all
tested chemokines on cells transfected with empty vector. Insert in B shows
the constitutive NFAT activity of US28 either without ligand (.), or under
influence of 107 M CX3CL1/fractalkine (4). Data are presented as
percentage modulation of basal (constitutive) receptor activity. (N = 3–6 for
all experiments).
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endogenous chemokine receptor, the mediated NFAT induc-
tion was negligible compared to the two virally encoded
chemokine receptors (Fig. 1A). The relation between the
maximum NFAT activity for ORF74 compared to US28
corresponded very well to the previously published magni-
tude of direct Gaq-protein activation measured as phospha-
tidyl-inositol (PI) turnover in transiently transfected COS-7
cells (Rosenkilde et al., 1999; Waldhoer et al., 2002). The
constitutive NFAT activation was also observed for both
receptors in COS-7 cells albeit at much lower induction
levels. In fact, only 3% of the basal and ligand-stimulated
activities in HEK-293 cells were obtained in COS-7 cells
(n = 13, data not shown) pointing to surprising differences
in signal transduction properties of these commonly used
cell lines.
Chemokine ligands modify the ORF74- and US28-induced
NFAT regulated transcription
The ORF74 elicited NFAT reporter activation could be
manipulated both positively and negatively in transiently
transfected HEK-293 cells (Fig. 2A). Thus, as expected
from studies of direct PLC activation (Arvanitakis et al.,
1997; Geras-Raaka et al., 1998b; Rosenkilde et al., 1999),
CXCL10/IP10 inhibited the basal NFAT reporter gene
activity with a potency (IC50) of 0.4 nM, while CXCL1/
GROa stimulated the activity with a potency (IC50) of 22
nM and an efficiency of 225% above the basal activity. The
inhibition corresponded very well to the previously pub-
lished potency of 1 nM for CXCL10/IP10 in the inhibition
of PLC activity [measured as phosphatidyl-inositol (PI)
turnover] (Rosenkilde et al., 1999). CXCL8/IL8 had no
effect of the NFAT activation—as expected from the neutral
nature of this ligand observed in PI-turnover experiments
(Rosenkilde et al., 1999). As a control experiment, we tested
the ability of CXCL8/IL8 to elicit NFAT activation viaCXCR2 expressing cells, and observed a 3-fold increase
and a potency of 1.2 nM, indicating that CXCL8/IL8
activates NFAT transcription provided expression of
CXCR2 (data not shown). The potency of CXCL1/GROa
in the NFAT activation of ORF74 was surprisingly low
compared to the previously published potency of 1.1 nM in
the ability of CXCL1/GROa to activate PI turnover (Rose-
nkilde et al., 1999), and due to this apparent low potency
compared to the potency observed in respect of PI turnover
(in COS-7 cells), we tested the three chemokines in tran-
siently transfected COS-7 cells. Albeit at lower induction
K.A. McLean et al. / Virolog244levels, we obtained similar dose–response curves in COS-7
cells with a potency for the inverse agonist CXCL10/IP10 of
0.8 nM and a potency for the agonist CXCL1/GROa of 20
nM, CXCL8/IL8 revealed the same neutral nature in these
cells (data not shown). Thus, COS-7 cells mirrored HEK-
293 cells in respect of potencies and the discrepancy
between the CXCL1/GROa potencies observed in these
two different Gaq-dependent assays could not be explained
by cellular differences.
US28 was negatively regulated by the chemokine
CX3CL1/fractalkine as shown in a gene dosage setup in
transiently transfected HEK-293 cells. Thus, a constant
concentration of CX3CL1/fractalkine (107 M) inhibited
the constitutive activity by 35–45% (Fig. 2B). This inverse
agonism is consistent with previous data of PLC activity
(Casarosa et al., 2001). The CC chemokines CCL5/
RANTES and CCL1/MCP1 showed no effect on the basal
NFAT-regulated activity for US28, again consistent with the
literature (Casarosa et al., 2001). As a control experiment,
we tested the ability of CCL5/RANTES and CCL1/MCP1
to elicit NFAT activation via CCR5 and CCR2 expressing
cells, respectively, and observed a 2–3-fold increase and
one-digit nanomolar potencies indicating that CCL5/
RANTES and CCL1/MCP1 activate NFAT transcription
provided expression of CCR5 and CCR2, respectively (data
not shown). None of the tested chemokines had any effect
on the NFAT activity level in cells transfected with the
empty vector (Fig. 2).Fig. 3. Inhibition of constitutive NFAT activity of ORF74 and US28 by comm
(pNFAT-Luc) and cDNA encoding ORF74 (A) or US28 (B). The cells were tre
staurosporin (Ss) at 25 and 50 nM (lined bars); PD 98059 (PD) at 10, 50, and 1
100 ng/ml (black bars); and U-73122 (U73) at 1 and 10 AM (horizontal lined bar
shown as gray bars next to the level of unspecific cellular activity. (N = 3–7 forORF74- and US28-mediated NFAT reporter induction is
affected similarly by selected pathway inhibitors
To characterize the pathway leading to NFAT activation
in ORF74- and US28-expressing cells, we treated the cells
with a panel of different pathway inhibitors: the calcineurin
inhibitor cyclosporin A, the PKC inhibitor staurosporin, the
MEK1 inhibitor PD 98059, and the p38 MAPK inhibitor
SB 202190, the Gai inhibitor pertussis toxin (Ptx) and the
PLC inhibitor U-73122. The direct interference of cyclo-
sporin A with the conventional pathway integrator calci-
neurin leading to NFAT activation was exploited as a control
experiment demonstrating the specificity of our reporter
assay, and as expected from this, cyclosporin A resulted in
inhibition of the constitutive activation of NFAT by both
ORF74 and US28 (Figs. 3A,B, respectively) with only
minor deviations. Thus, 1 nM cyclosporin A resulted in a
reduction in the reporter gene expression to about 83% for
ORF74 and 75% for US28, and 10 nM reduced the
expression to 15% and 25%, respectively. In both receptors,
the NFAT-mediated reporter activity was fully blocked at 50
nM cyclosporin A resembling the empty vector level. PKC
represents a well-described alternate pathway leading to c-
fos/jun activation and thus enhancement of NFAT-mediated
transcription (Rao et al., 1997). PKC inhibition by staur-
osporin resulted in a partial inhibition to about 50% of the
basal activity at the highest dose (50 nM) for both receptors
(Figs. 3A,B). Also, the MAP-kinase inhibitors PD 98059
y 325 (2004) 241–251on kinase inhibitors. HEK-293 cells were transfected with NFAT reporter
ated with either cyclosporin A (CsA) at 1, 10, and 50 nM (black bars);
00 AM; or SB 202190 (SB) at 5 and 10 AM (light gray bars); Ptx (Ptx) at
s) Data are presented as percentage inhibition of basal receptor expression
all experiments).
50
100
Fig. 4. ORF74 and US28 mediate constitutive activation of CREB trans-
reporting system. HEK-293 cells were transiently transfected with the
CREB reporter (pFA2-CREB), the trans-activator (pFR-Luc) plasmid, and
the receptor cDNA. From left: ORF74 (gray bar), US28 (lined bar),
CXCR2 (black bar), and empty vector, pTEJ8 (white bar). Data represent
percentage activity of the basal activity for ORF74. Insert: Dose-dependent
CREB activity for ORF74 (n), compared to the empty vector pTEJ8 (.).
(N = 3–6 for all experiments).
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and US28 (Figs. 3A,B) within the chosen concentrations
(10, 50, and 100 AM for PD 98059 and 5 and 10 AM for SB
202190). Blocking Gai by Ptx (100 ng/ml) resulted in a
surprising inhibition to 60% (Fig. 3), whereas PLC-block-
ade by U-73122 resulted in 50% blockade of the basal
NFAT activity. These data suggest that the Gai activation
may be at least as important as Gaq in mediating NFAT
activation downstream of US28 and ORF74. The content of
the PLCh2 isoform—for which the hg-dimer released from
activated Gai has highest affinity for (Katz et al., 1992)—in
HEK-293 cells makes it most likely that the effect of Ptx on
the NFAT activity is through inhibition of the hg-mediated
PLC activation. In fact, Ptx inhibition of constitutive and/or
ligand-induced NF-nB activation (also dependent on PLC)
by ORF74-HHV8 has been reported previously by several
groups (Couty et al., 2001; Montaner et al., 2001; Shepard
et al., 2001). The whole panel of inhibitors was tested on
CXCL1/GROa stimulated ORF74 and CCL5/RANTES
bound US28 (both 107 M) with no differences from the
influence of the inhibitors on the basal NFAT activity (data
not shown). Thus we conclude that the ligand-dependent
and ligand-independent NFAT-mediated transcription activ-
ities are regulated similar and that the NFAT reporter activity
measured reflects real NFAT induction mediated through
calcineurin. We furthermore conclude that ORF74 and
US28 activate Gai, PLC, p44/42 MAP kinase, p38 MAP
kinase, and PKC at similar levels and that these pathways
converge on the calcineurin/NFAT pathway leading to high
levels of NFAT-mediated transcription.
ORF74 and US28 constitutively activate the transcription
factor CREB
The transcription activation mediated by CREB is clas-
sically considered a downstream effect of activation of Gas-
coupled receptors that in turn activate adenylate cyclase.
However, another way to obtain activation of CREB is via
Gaq, mediated by the calcium released upon interaction of
the formed IP3 with its receptor via Calmodulin-dependent
kinases (Shaywitz and Greenberg, 1999). In addition, it has
become increasingly clear that several nonclassical path-
ways are capable of activating CREB including p38 MAP
kinase, p44/42 MAP kinase, and calcium through activation
of a calcium-sensitive adenylate cyclase (Shaywitz and
Greenberg, 1999). Thus, CREB can be considered an
integrator of multiple transcription factors and was conse-
quently selected for further characterization. HEK-293 cells
transiently expressing CREB-sensitive reporter plasmids
together with either ORF74 or US28 showed a robust
ligand-independent CREB activation, whereas this was not
the case for the expression of CXCR2 or empty vector
(Fig. 4). Increasing amounts of DNA revealed increasing
levels of constitutive activity for the ORF74 receptor (Fig.
4) as well as for the US28 receptor (Fig. 5B). The level of
constitutive activity for the two wild-type receptors weresurprisingly similar with US28 displaying 80% of the basal
activity for ORF74 (Fig. 4)—a ratio that is higher than the
respective NFAT signaling ratio of 30% (Fig. 1).
Chemokines modify the ORF74- and US28-induced
CREB-regulated transcription
Transiently transfected HEK-293 cells expressing
ORF74 or US28 were treated with the same chemokines
as employed in the NFAT experiments. Again, dose–re-
sponse curves on ORF74 revealed inverse agonistic prop-
erties for CXCL10/IP10 with an inhibition of the basal
CREB activity at a potency of 2.5 nM and agonist properties
for CXCL1/GROa with an efficiency of 250% above the
basal activity and a potency of 3.3 nM. CXCL8/IL8
displayed a weak stimulation compared to basal ligand-
independent ORF74-induced CREB expression (Fig. 5A).
As a control experiment, we tested the ability of CXCL8/
IL8 to elicit CREB activation via CXCR2-expressing cells,
and observed a 2-fold increase with a potency of 0.5 nM,
indicating that CXCL8/IL8 activates CREB transcription
provided expression of CXCR2 (data not shown). Thus, for
all three ligands, we found potencies and efficacies in CREB
activation in the same range as we previously found in PI
turnover (Rosenkilde et al., 1999).
Fig. 5. Chemokine modification of ORF74-mediated CREB activation.
HEK-293 cells were transiently transfected with ORF74, CREB reporter
(pFA2-CREB) and trans-activator (pFR-Luc) plasmid and were treated by
increasing concentrations of the chemokines CXCL1/GROa (5), CXCL8/
IL8 (E), and CXCL10/IP10 (n) (A). In B, US28 under influence of
107 M of different chemokines, CCL5/RANTES (black bar), CCL1/
MCP1 (lined bar), and CX3CL1/fractalkine (light gray bar) is shown
together with the effect of all tested chemokines on cells transfected with
empty vector. Insert in B shows the constitutive NFAT activity of US28
either without ligand (.), or under influence of 107M CX3CL1/
fractalkine (D). Data are presented as percentage modulation of basal
(constitutive) receptor activity. (N = 3–6 for all experiments).
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as shown in a gene dosage setup in transiently transfected
HEK-293 cells. Thus, a constant concentration of CX3CL1/
fractalkine (107 M) inhibited the constitutive activity by
50–55% (Fig. 5B). This inverse agonism is consistent with
previous data of PLC activity (Casarosa et al., 2001). The
CC chemokines CCL5/RANTES and CCL1/MCP1 showed
no effect on the basal CREB regulated activity for US28,
again in consistency with the literature (Casarosa et al.,
2001). As a control experiment, we tested the ability of
CCL5/RANTES and CCL1/MCP1 to elicit CREB activationvia CCR5- and CCR2-expressing cells, respectively, and
observed a 2–3-fold increase and one-digit nanomolar
potencies indicating that CCL5/RANTES and CCL1/
MCP1 activate CREB provided expression of CCR5 and
CCR2, respectively (data not shown). None of the tested
chemokines had any effect on the CREB activity level in
cells transfected with the empty vector (Fig. 5).
ORF74- and US28-mediated CREB reporter induction is
similarly affected by selected pathway inhibitors
To estimate the contribution of the pathways to ORF74-
and US28-mediated CREB activation, the whole panel of
pathway inhibitors was applied to transiently transfected
HEK-293 cells expressing CREB reporter and activator
plasmid together with the receptor DNA (Fig. 6). As
expected, the calcineurin inhibitor cyclosporin A did not
affect the constitutive CREB activity. In contrast, the
ORF74- and the US28-mediated CREB activities were
inhibited to 35–40% and US28 mediated by 50 nM of the
PKC inhibitor staurosporin. Also, the PLC inhibitor U-
73122 inhibited both receptors similarly to around 60% of
basal activity. At high doses, the MAP-kinase inhibitors (PD
98059 and SB 202190) inhibited basal CREB-mediated
transcription to 55–70%, whereas PD 98059 at a lower
dose stimulated the transcription for both receptors at 110–
145%. Ptx showed no effect, as expected from the nature of
CREB-mediated transcriptional activation. Taken together,
these results suggest that both receptors were similarly
dependent of PKC, PLC, and the MAP kinases (mainly
p38) as mediators of CREB activation in HEK-293 cells and
that Calmodulin/calcium had no role in the CREB activa-
tion, for both receptors.Discussion
US28 and ORF74 in the biology of human CMV and HHV8
Both receptors are highly constitutively active, and
ORF74 has been implicated in development of experimental
Kaposi’s sarcoma-like lesions in mice. Human CMV has
tropism for myeloid cells and HHV8 have tropism for
lymphoid and myeloid cells, yet the human CMV is believed
to also establish latent infection in the endothelium and
smooth muscle cells of large central arteries, whereas
HHV8 likely infects the dermal microvasculature (Britt and
Alford, 1996; Panyutich et al., 1998; Reinhardt et al., 2002).
Correspondingly, US28 binds CC-chemokines and the
CX3C-chemokine CX3CL1/fractalkine that are expressed
during inflammation and viral infection of the large arteries,
whereas ORF74 binds and is regulated by CXC-chemokines
expressed during inflammation of the skin and in Kaposis
sarcoma lesions infected with HHV8 (Breuer-McHam et al.,
2000; Engelhardt et al., 1998; Greaves et al., 2001; Seino et
al., 1995). Both receptors are expressed early during viral
Fig. 6. Inhibition of constitutive CREB activity of ORF74 and US28 by common kinase inhibitors. HEK-293 cells were transiently transfected with the CREB
reporter (pFA2-CREB), the trans-activator (pFR-Luc) plasmid, and the receptor cDNA encoding either ORF74 (A) or US28 (B). The cells were treated with
either cyclosporin A (CsA) at 50 nM (black bars); staurosporin (Ss) at 25 and 50 nM (lined bars); PD 98059 (PD) at 10, 50, and 100 AM; or SB 202190 (SB) at
5 and 10 AM (light gray bars), Ptx (Ptx) at 100 ng/ml (black bars) and U-73122 (U73) at 1 and 10 AM (horizontal lined bars). Data are presented as percentage
inhibition of basal receptor expression shown as gray bars next to the level of unspecific cellular activity. (N = 3–6 for all experiments).
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the natural viral reservoirs are limited. As transgenically
expressed ORF74 is sufficient to drive the development of
Kaposi’s sarcoma-like lesions of the skin, presumably by
infiltrating cells expressing paracrine effector molecules,
US28 may possibly initiate or contribute to CMV-associated
atherosclerotic lesions in a similar manner (Cesarman et al.,
2000; Yang et al., 2000). This is supported by the ability of
US28 to mediate the migration of vascular arterial smooth
(Streblow et al., 1999). We here report that the complex and
large array of intracellular signaling pathways initiated by
both receptors converge to induce transcription activation in
a more similar way than what could have been anticipated
from the reported upstream kinases and phospholipases,
supporting putative similar functions for these two receptors.
NFAT activation in inflammation and vascular development
With several reporter assays available that are likely
induced by the known ORF74 and US28 activated pathways,
we focused on NFAT as most of the knowledge of ORF74
biology is concerned with Kaposi’s sarcoma. The NFAT
transcription factors are known inducers of several inflam-
matory genes including IL-2 (the promoter of which is part
of the NFAT reporter plasmid vector), IL-4, and IL-12, and is
highly important for lytic viral replication—an event pre-
ceding development of Kaposi’s sarcoma (Goudsmit et al.,
2000; Moore et al., 1996; Zoeteweij et al., 2001). ORF74 and
US28 both induced NFAT transcription activity in a gene-dosage-dependent manner and this activity could be effi-
ciently inhibited by cyclosporin A confirming the readout to
be Calmodulin/NFAT dependent. In fact, constitutive NFAT
activation by ORF74 has also been presented in primary
effusion lymphoma cells (Cannon and Cesarman, 2004;
Cannon et al., 2003). To further characterize the signaling
pathways utilized for the NFAT activation in HEK-293 cells
for both receptors, the pathway inhibitors staurosporin (PKC
inhibitor), PD 98059 (MEK1 inhibitor), SB 202190 (p38
MAPK inhibitor), Ptx (Gia inhibitor), and U-73122 (PLC
inhibitor) were added and investigated for their effect on
NFAT-mediated transcription (Fig. 3). These experiments
demonstrated partial reduction in ligand-mediated and basal
NFAT transcription by inhibition of PKC, MEK1, p38
MAPK, Gia (NFAT activation via activated Ghg dimeric
subunits released from activated Gai), and PLC, but more
importantly showed that ORF74 and US28 were inhibited at
almost identical levels. PKC contribution to NFAT activation
is not surprising as PKC is a known inducer of c-fos/jun that
potentiates the NFAT activity (Rao et al., 1997). The NFAT
inhibition of US28 by PD 98059 supports a previously found
activation of p44/42 MAP kinase by US28 expressed in
HEK-293 cells (Billstrom et al., 1998). p38 MAPK signaling
has previously been reported downstream of both receptors
(Sodhi et al., 2000; Waldhoer et al., 2002). Also, Gai- and
Gaq-mediated signal transduction activities have been
reported from both receptors (Arvanitakis et al., 1997; Bill-
strom et al., 1998; Geras-Raaka et al., 1998a; Rosenkilde et
al., 1999). It is therefore not surprising that NFAT inhibition
Fig. 7. Cellular localization of ORF74 and US28. HEK-293 cells were
transiently transfected with the two receptors fused to green fluorescent
protein (GFP) and cultured on poly-D-lysine- and collagen-treated glass
cover slips. The cover slips were transferred to slides using Vectashield
mounting medium after fixation with 3% paraformaldehyde. Finally, the
cells were analyzed in a confocal microscope. Left panel, expression of
ORF74 being mainly localized to cell surface, as previously shown
(Schwarz and Murphy, 2001). Right panel, expression of US28 being
mainly localized intracellularly in multivesicular bodies, as previously
shown (Fraile-Ramos et al., 2001).
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was only partial and suggests that other factors (i.e., MAPK,
PKC) mediated through other G proteins than Gaq to be at
least as important in mediating ORF74- and US28-induced
gene transcription. In conclusion, the NFAT activity ob-
served in our system is regulated by at least four different
pathways that each contributes at similar levels in both
receptors, thus giving evidence to common upstream mech-
anisms of ORF74 and US28 signaling. The low potency of
CXCL1/GROa in respect of NFAT activation (Fig. 2)
compared to CREB activation (Fig. 5) and PI turnover
(Rosenkilde et al., 1999) could not be explained by differ-
ences in cell types since we tested HEK-293 and COS-7
cells. However, it could be due to the high constitutive
activity of ORF74 and the subsequent limitations of the
NFAT signaling cascade–being dependent on calcium re-
lease—to further respond upon agonist application. To
support this, we observed that CXCL1/GROa indeed acti-
vated the NFAT pathway with high potency (EC50 of 1 nM)
in cells expressing the CXCR2 receptor (data not shown).
Constitutive CREB activation—a robust and important gene
regulator
Having analyzed the activation of NFAT, we next focused
on the possible activation of cAMP response element (CRE)
carrying promoters by cAMP response element binding
protein (CREB). CRE activating element is generally not
considered as an activator of inflammatory responses but is
an important constituent of the promoters of more than a
hundred identified human genes and several viral genes, and
serves functions ranging from metabolism, nerve growth,
apoptosis inhibition, to regulation of virally encoded genes
and promoters (Shaywitz and Greenberg, 1999). The activa-
tion of CREB downstream of PKC and Calmodulin is well
established (Shaywitz and Greenberg, 1999) and thus it was
not surprising to see the gene-dose-dependent CREB acti-
vation by both ORF74 and US28. The CREB activation was
screened through the same panel of pathway inhibitors as the
NFAT response and again we observed a nearby identical
pattern of ORF74- and US28-mediated reporter activity with
a partial inhibition by many of the inhibitors. However, as
expected, cyclosporin A and Ptx had no effect on the
consistency with the Gaq/Gas nature of the CREB activa-
tion. Of note is the discrepancy in the ratios of basal US28-
mediated activity compared to basal ORF74-mediated activ-
ity as we observed relatively higher level of CREB (80%)
than of NFAT activation (30%) for US28 (compared to
ORF74), which could suggest an alternative pathway of
CREB, but not NFATactivation for US28; yet such pathways
remains to be identified. The differences in the total basal
activity for the two receptors could very well be due to the
large difference in cellular expression, as 80–90% of totally
expressed US28 is located intracellularly in multivesicular
bodies (Fraile-Ramos et al., 2001), whereas ORF74 is
mainly expressed at the cell surface (Schwarz and Murphy,2001) (Fig. 7). The intracellular pool of US28 could very
well contribute selectively in the CREB, but not in the NFAT
activation, and thereby explain this discrepancy.
Similarities and differences in the signaling pattern of US28
and ORF74
In summary, we have here presented a comparative
analysis of multiple signaling pathways induced by two
virally encoded chemokine receptors. Our results suggest
that despite their different heritage in the mammalian
genome, and different regulation by endogenous chemo-
kines, these two receptors are remarkably similar in their
signaling profile. The ligand-regulated activities are quite
different because ORF74 as mentioned previously is mod-
ulated by several CXC-chemokines acting as agonists,
neutral ligands, and inverse agonists, whereas US28 primar-
ily responds to the inverse agonist CX3CL1/fractalkine, but
not to the many CC-chemokines (in respect of PLC, CREB,
and NFAT activation) that bind with high affinity to this
receptor. Recently, it was suggested that the lack of activa-
tion by endogenous chemokines—that bind with high af-
finity to US28—could be a consequence of the intracellular
localization of US28 (Fig. 7) (Fraile-Ramos et al., 2001)
because mutated variants of US28 with highly increased cell
surface expression (and a subsequent decrease in the intra-
cellular pool) in fact responded very well to endogenous
chemokines (Waldhoer et al., 2003).
Is there a common role for these constitutively active
receptors in viral biology?
The pathways presented here are known activators of
cellular and viral genes including inflammatory cytokines
K.A. McLean et al. / Virology 325 (2004) 241–251 249upregulated in diseases associated with the two viruses,
housekeeping genes, antiapoptotic factors, and the viral
transactivator of HHV8 (Gwack et al., 2001; Pugazhenthi
et al., 2000; Zoeteweij et al., 2001). In addition, the ORF74
from HHV8 has been directly shown to induce expression
from several viral promoters (Chiou et al., 2002). The
remarkable similarities in the signaling of ORF74 and
US28 presented here suggest that these receptors may serve
similar roles in the coordination of host and virally encoded
gene expression, suggesting similar roles in virus pathogen-
esis. A confirmation of such a role for US28 will depend on
future transgenic or recombinant virological studies.Materials and methods
DNA constructs
ORF74 was cloned from a skin biopsy of a Kaposi’s
sarcoma lesion taken from a HIV-1-infected person as
previously described (Rosenkilde et al., 1999) (Gen-
BANKk accession number U24275). The US28 receptor
and the human CXCR2 receptor were generously provided
by Timothy N.C. Wells, Serono Research Pharmaceuticals,
Geneva, Switzerland. All receptor constructs were cloned
into the eukaryotic expression vector pTEJ8 (Johansen
et al., 1990). CREB reporter (pFA2-CREB) and trans-
activator (pFR-Luc) plasmids were kindly provided by
Lundbeck, Denmark, and cis-reporter (pNFAT-Luc) was
purchased from Stratagene.
Materials
The human chemokines were purchased from Peprotech
Inc. or made in house by Thomas P. Boesen through E. coli
expression, purification, and refolding (CXCL8/IL8). Lip-
ofectAMINEk 2000 Reagent and OPTIMEM 1 (Cat. No
51985-026) were purchased from Life Technologies.
Fugene 6 Transfection Reagent was from Roche Diagnos-
tics, Switzerland. Lyophilized Substrate Solution-LucLite
was purchased from Packard. MEK1 inhibitor (PD
98059)—which inhibits P42/44 MAP kinase activation—
was purchased from Cell Signaling TECHNOLOGYk; p38
MAPK inhibitor (SB 202190) was from CALBIOCHEMR;
cyclosporin A, LY 294002, and staurosporin were from
Sigma-Aldrich Co.; Ptx was from Sigma Chemical Co.; and
U-73122 and LY 294002 were from Biosource, CA. All
chemicals were solubilized in DMSO except for Ptx, which
was solubilized in glycerol.
Tissue culture and transfection
COS-7 cells were grown at 10% CO2 and 37 jC in
Dulbecco’s modified Eagle’s medium with glutamax
(Gibco, Cat. No 21885-025) adjusted with 10% fetal bovine
serum, 180 u/ml penicillin and 45 Ag/ml streptomycin(PenStrep). HEK-293 cells were grown in DMEM adjusted
to contain 4500 mg/l Glucose (Cat. No 31966-021) with the
same amount FBS and PenStrep as the COS-7 medium at
10% CO2 and 37 jC. During luciferase-based assay, the cell
media was modified to include heat-inactivated FBS and no
PenStrep. Transfection for the luciferase-based assays was
performed by cationic lipid reagent method with Lip-
ofectAMINEk 2000 Reagent in the serum-free media
OPTIMEM.
Confocal microscopy
HEK293 cells were cultured on poly-D-lysine- and col-
lagen-treated glass cover slips in 6-well culture plates and
transiently transfected with 1 Ag receptor cDNA [receptor
fused to green fluorescent protein (GFP)] using Fugene 6
Transfection Reagent according to the manufacturer’s
instructions. Two days after transfection, the cells were
fixed with 3% paraformaldehyde in PBS for 10 min at
RT, and washed twice in PBS. The coverslips were trans-
ferred to slides using Vectashield mounting medium from
Vectorlab (Burlingame, CA), and the cells were analyzed
using a Zeiss ConfoCor2 LSM-FCS confocal microscope
(Carl Zeiss, Oberkochen, Germany) equipped with an Ar-
gon/2 laser (488 nm) using an apochromat 63/1.4 Oil DIC
immersion lens.
Constitutive NFAT cis-reporting and CREB trans-reporting
assay
Cells were seeded in culture plates 24 h before transfec-
tion at 35000 cells/well and were transfected with 50 ng/
well (cis)-reporter plasmid (pNFAT-Luc) and rated 0–50 ng/
well of receptor plasmid. For the trans-reporting system,
50 ng/well trans-activator plasmid (pFR-Luc) was added
together with 6 ng/well of the trans-reporter (pFA2-CREB)
and receptor plasmids. The CCR2, CCR5, and CXCR2
transfection included the promiscuous chimeric G protein
GaD6qi4myr, kindly provided by Evi Kostenis (7TM
Pharma, Denmark). Twenty-four hours after transfection,
the cells were washed twice in Dulbecco PBS and the
luminescence was measured in a microplate scintillation
and luminescence counter (Top-counter, Packard) after
10-min incubation in 100 Al Dulbecco PBS together with
100 Al Luc-Lite substrate.
Ligand modification assay
For the chemokine dose–response curves, the cells were
transfected with 10 ng/well receptor cDNA and the above-
mentioned concentrations of reporter and activator plasmids
and chemokines added at concentrations ranging from
1011 to 107 M. Alternatively, a constant chemokine
concentration (107M) was added to the gene-dosage
experiments with receptor cDNA (see above). In both
cases, the chemokines were immediately added following
K.A. McLean et al. / Virology 325 (2004) 241–251250transfection and 18 h post transfection, and luminescence
was measured 24 h post transfection as described above.
All determinations were done in triplicates and all assays
were repeated at least 3 times.
Pathway inhibition assays
The cells were transfected with 50 ng/well receptor
cDNA and the above-mentioned concentrations of reporter
plasmids. Toxins and kinase inhibitors were immediately
added after transfection and luminescence was measured
24 h posttransfection as described above. All determinations
were made in quadruples and all assays were repeated at
least 3 times (Graef et al., 2001a).
Calculations
The GraphPad Software PrismR was used for the anal-
ysis of the results. Receptor gene-dosage data are drawn at
either original counts or normalized with the maximum
expression of ORF74 representing 100%. The dose–re-
sponse curves were analyzed by the nonlinear regression
method and sigmoidal dose–response curve determining
IC50 values. Signaling modification data with addition of the
various inhibitors was normalized with the respective
DMSO and glycerol control.Acknowledgments
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